Glanbia’s latest twist is not a protein powder or a bar, but a test run of ChampionSips, a non alcoholic Optimum Nutrition beer with 10g of protein, aimed at a new social drinking occasion. Investors who held Glanbia from the start of the year are up 37.3%, including dividends. If you were deciding back on 1 January, what would you have needed to believe about this kind of expansion to justify buying before any of that was visible?
This theme extends beyond Glanbia. See which of 126 healthcare AI stocks may still merit a closer look.
The Glanbia Debate You Would Have Been Weighing
The shares cost €14.59 at the start of the period, so any decision on Glanbia rested on which story about its future you found more convincing.
On the optimistic side, the bull Narrative argued that a Fair Value of €16.77, a price suggested by its assumptions, made sense if health and dairy nutrition kept widening Glanbia’s reach and revenue grew 2.4% a year with profit margins rising toward 7.4% on a 14.7x future P/E.
The bear Narrative pointed to a Fair Value of €13 and focused on the risk that growing plant-based demand and ESG pressure would weaken dairy, even if revenue still grew 2.1% and margins climbed to 8.1% on an 11.4x future P/E.
What The Results Changed In The Glanbia Argument
The launch of ChampionSips under Optimum Nutrition backed the optimistic view that Glanbia could stretch its brands into new drinking occasions. H1 2026 added harder numbers. Revenue moved to US$2,079.4m and net income to US$153.8m, with net margin at 7.4%. That margin aligned closely with the optimistic case, although analyst concerns about future whey costs kept the cautious story alive.
The key lesson is simple. When a thesis rests on better profitability, keep checking the reported net margin against the original assumption and ask whether product launches like ChampionSips are actually visible in those numbers.
What Glanbia’s Run Leaves You Paying For Today
Glanbia now trades at €19.42, with the selected bullish Narrative arguing that its Fair Value sits above the current price. That view leans heavily on cost savings, capacity build out and brand resilience in Performance Nutrition and Health and Nutrition.
The Narrative contends today’s price still does not fully credit Glanbia successfully executing its transformation program while managing elevated whey and other input costs.
"Execution of a group wide transformation program, including a new global supply chain structure, IT operating model, automation and AI based tools, now targeted to deliver about $70m of annual savings by 2027 with around 40% expected by the end of 2026, gives Glanbia more room to improve EBITDA margin and earnings."
The price and this Narrative do not agree. → Uncover what this Narrative says Glanbia is actually worth
Which Company Could Surprise You Next?
You may be late to this rally, but that does not have to mean arriving late to every opportunity. Start with companies whose prices leave room for a different view of their future. Here are three trading below our estimates.
- Company 1 - 36% below our estimate - builds and services power and refrigeration systems for data centers and infrastructure clients.
- Company 2 - 21% below our estimate - expands healthcare outsourcing contracts as AI tools influence claims and care management.
- Company 3 - 34% below our estimate - folds acquired engineering consultancies into a platform focused on infrastructure and water programs.
Three companies from the same screener. Open the full list of 224 companies trading below our fair value estimates →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com